1. Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. (21st February 2018) Authors: Marra, Fiona; Höner zu Siederdissen, Christoph; Khoo, Saye; Back, David; Schlag, Michael; Ouwerkerk‐Mahadevan, Sivi; Bicer, Ceyhun; Lonjon‐Domanec, Isabelle; Jessner, Wolfgang; Beumont‐Mauviel, Maria; Kalmeijer, Ronald; Cornberg, Markus Journal: British journal of clinical pharmacology Issue: Volume 84:Number 5(2018:Nov.) Page Start: 961 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study. Issue 3 (4th May 2017) Authors: Forns, Xavier; Berenguer, Marina; Herzer, Kerstin; Sterneck, Martina; Donato, Maria Francesca; Andreone, Pietro; Fagiuoli, Stefano; Cieciura, Tomasz; Durlik, Magdalena; Calleja, Jose Luis; Mariño, Zoe; Shukla, Umesh; Verbinnen, Thierry; Lenz, Oliver; Ouwerkerk‐Mahadevan, Sivi; Peeters, Monika; Ja... Journal: Transplant infectious disease Issue: Volume 19:Issue 3(2017) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Issue 1 (January 2015) Authors: Reddy, K Rajender; Zeuzem, Stefan; Zoulim, Fabien; Weiland, Ola; Horban, Andrzej; Stanciu, Carol; Villamil, Federico Guillermo; Andreone, Pietro; George, Jacob; Dammers, Elisabeth; Fu, Min; Kurland, Darryl; Lenz, Oliver; Ouwerkerk-Mahadevan, Sivi; Verbinnen, Thierry; Scott, Jane; Jessner, Wolfgang Journal: Lancet infectious diseases Issue: Volume 15:Issue 1(2015:Jan.) Page Start: 27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Issue 1 (January 2015) Authors: Reddy, K Rajender; Zeuzem, Stefan; Zoulim, Fabien; Weiland, Ola; Horban, Andrzej; Stanciu, Carol; Villamil, Federico Guillermo; Andreone, Pietro; George, Jacob; Dammers, Elisabeth; Fu, Min; Kurland, Darryl; Lenz, Oliver; Ouwerkerk-Mahadevan, Sivi; Verbinnen, Thierry; Scott, Jane; Jessner, Wolfgang Journal: Lancet infectious diseases Issue: Volume 15:Issue 1(2015:Jan.) Page Start: 27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗